Results 141 to 150 of about 140,483 (294)

Tolerability and safety of a new elimination diet for pediatric eosinophilic gastritis and duodenitis

open access: gold, 2022
Saori Nagashima   +18 more
openalex   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

<i>Helicobacter pylori</i> and Cancer: What's the Link? [PDF]

open access: yesClin Exp Gastroenterol
Merola E, Pes GM, Graham DY, Dore MP.
europepmc   +1 more source

Volatile organic compounds discriminate between eosinophilic and neutrophilic inflammationin vitro [PDF]

open access: hybrid, 2016
Florence Schleich   +5 more
openalex   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

open access: yesBMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou   +6 more
wiley   +1 more source

Mixed cholangiopathy with eosinophilic and autoimmune features: a case report. [PDF]

open access: yesJ Med Case Rep
Shen H   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy